The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Allogeneic Cellular Vaccine 1650-G for Non-Small Cell Lung Cancer
Official Title: Allogeneic Cellular Vaccine 1650-G for Non-Small Cell Lung Cancer (NSCLC)
Study ID: NCT00654030
Brief Summary: Rationale: Vaccines made from allogeneic tumor cells may help the body build an effective immune response to kill tumor cells. The Purpose of this study is to evaluate the effects of a lung cancer vaccine in patients with Stage I or Stage II Non-Small Cell Lung Cancer (NSCLC) after completion of initial definitive therapies.
Detailed Description: The study is an open label investigation of the cellular vaccine called 1650-G. Patients receive 2 vaccine injections intradermally in the thigh given 4 weeks apart. Patients will be followed weekly after each vaccine injection and then monthly for 4 months. Patient follow-up continues with evaluations at 6 months and 1 year after receiving the first vaccine injection. Immunologic responses to the vaccine will be assessed from blood samples obtained at each visit following immunizations.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Commonwealth Cancer Center, Danville, Kentucky, United States
University of Kentucky, Lexington, Kentucky, United States
University of Louisville Hospital, Louisville, Kentucky, United States
Owensboro Medical Health System, Owensboro, Kentucky, United States
Name: Edward A Hirschowitz, MD
Affiliation: University of Kentucky
Role: STUDY_CHAIR
Name: John R Yannelli, PhD
Affiliation: University of Kentucky
Role: STUDY_CHAIR
Name: Goetz H Kloecker, MD
Affiliation: University of Louisville
Role: PRINCIPAL_INVESTIGATOR
Name: Thomas R Baeker, MD
Affiliation: Commonwealth Cancer Center
Role: PRINCIPAL_INVESTIGATOR
Name: Dattatraya S Prajapati, MD
Affiliation: Owensboro Medical Health System
Role: PRINCIPAL_INVESTIGATOR